Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223737 | 1.00 | AR (0.40) | ARCTSLSMN1; SMN2PGRGAA | |
| SCHEMBL223295 | 0.92 | AR (0.40) | ARPGR | |
| SCHEMBL223294 | 0.92 | AR (0.40) | ARPGR | |
| SCHEMBL223681 | 0.88 | AR (0.38) | ARCTSLSMN1; SMN2PGRGAA | |
| SCHEMBL223682 | 0.88 | AR (0.38) | ARCTSLSMN1; SMN2PGRGAA | |
| SCHEMBL220764 | 0.80 | AR (0.49) | ARPGR | |
| SCHEMBL220763 | 0.80 | AR (0.49) | ARPGR | |
| SCHEMBL1366149 | 0.80 | POLB (0.42) | ARSMN1; SMN2PGR | |
| SCHEMBL1366146 | 0.80 | POLB (0.42) | ARSMN1; SMN2PGR | |
| SCHEMBL2760518 | 0.80 | AR (0.48) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004270-A1 | Selective Androgen Receptor Modulators | AR, NR3C2, NR5A1 | AR 1/4885CTSL 4801/4885SMN1; SMN2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.